Ignite Creation Date:
2024-05-05 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 9:57 AM
Study NCT ID:
NCT00780052
Status:
COMPLETED
Last Update Posted:
2016-09-26
First Post:
2008-10-24
Brief Title:
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Study Overview
Official Title:
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
UPCC 04701
Brief Summary:
The purpose of this study is to evaluate whether C-myb Antisense AS Oligonucleotides ODNsis a possible treatment modality for advanced hematologic malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None